GH Research raises $125 million for development of inhaled 5-MeO-DMT

GH Research Ireland has closed a $125 million Series B financing round to fund development of its GH001 inhaled 5-MeO-DMT, the company announced. 5-MeO-DMT is psychedelic found in the venom of certain toads. GH is currently developing GH001 for the treatment of treatment resistant depression, and according to the announcement, “The company’s goal is to administer GH001 in a single-day individualized dosing regimen that enables patients to achieve a rapid and durable remission with convenient administration.”

A Phase 1/2 trial of GH001 in patients with treatment resistant depression is ongoing, and GH said that it plans to develop GH001 for additional indications. The company is also developing an injectable formulation of 5-MeO-DMT.

Read the GH Research press release.

Share

published on

December 9-December 11: DDL 2026, Edinburgh, Scotland

April 27-30: RDD Europe 2027, Antibes, France

May 30-June 2: ISAM Congress 2027, Dublin, Ireland

June 23: SMI London, London, UK